KR20230169950A - Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체 - Google Patents

Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체 Download PDF

Info

Publication number
KR20230169950A
KR20230169950A KR1020237032819A KR20237032819A KR20230169950A KR 20230169950 A KR20230169950 A KR 20230169950A KR 1020237032819 A KR1020237032819 A KR 1020237032819A KR 20237032819 A KR20237032819 A KR 20237032819A KR 20230169950 A KR20230169950 A KR 20230169950A
Authority
KR
South Korea
Prior art keywords
seq
set forth
ser
sequence
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237032819A
Other languages
English (en)
Korean (ko)
Inventor
로버투스 코르넬리스 루버스
더 블리엣 요하네스 젤레 반
훌식 데이비드 루트제
폴 윌렘 헨리 아이다 파렌
주르젠 마티스 루벤
샬롯 메레트 무셋
Original Assignee
라바 테라퓨틱스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라바 테라퓨틱스 엔.브이. filed Critical 라바 테라퓨틱스 엔.브이.
Publication of KR20230169950A publication Critical patent/KR20230169950A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237032819A 2021-02-26 2022-02-28 Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체 Pending KR20230169950A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21159698.6 2021-02-26
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US63/166,339 2021-03-26
US202163274709P 2021-11-02 2021-11-02
US63/274,709 2021-11-02
EP21211114.0 2021-11-29
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (1)

Publication Number Publication Date
KR20230169950A true KR20230169950A (ko) 2023-12-18

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032819A Pending KR20230169950A (ko) 2021-02-26 2022-02-28 Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체

Country Status (9)

Country Link
US (1) US20240141071A1 (https=)
EP (1) EP4298125A1 (https=)
JP (1) JP2024507937A (https=)
KR (1) KR20230169950A (https=)
AU (1) AU2022225091A1 (https=)
BR (1) BR112023017099A2 (https=)
CA (1) CA3209454A1 (https=)
MX (1) MX2023009950A (https=)
WO (1) WO2022180271A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP3129404B1 (en) * 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
BR112020020604A2 (pt) * 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Ｃｄ１２３結合性ポリペプチド及びその使用
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY

Also Published As

Publication number Publication date
BR112023017099A2 (pt) 2023-11-21
MX2023009950A (es) 2023-11-10
EP4298125A1 (en) 2024-01-03
JP2024507937A (ja) 2024-02-21
US20240141071A1 (en) 2024-05-02
WO2022180271A1 (en) 2022-09-01
AU2022225091A1 (en) 2023-09-07
CA3209454A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
TWI830151B (zh) 抗GPRC5DxBCMAxCD3三特異性抗體及其用途
KR20220050971A (ko) 신규 항-cd39 항체
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
KR20230169950A (ko) Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
CN114746119A (zh) 抗-ceacam抗体及其用途
KR20240023653A (ko) 항-cd3 항체 및 그의 용도
WO2025120583A2 (en) CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
KR20240007767A (ko) CLDN18.2에 대한 단클론 항체 및 이의 Fc 조작된 형태
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors
WO2026002175A1 (zh) 靶向ilt7和cd89的髓细胞衔接子抗体及其用途
TW202412838A (zh) 包含結合γ-δ T細胞受體之抗體之組合物
WO2025083273A1 (en) Binding molecules
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
CN121127496A (zh) 抗Vβ17/抗CD123双特异性抗体
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230925

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250220

Comment text: Request for Examination of Application